Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Total Valuation
Biogen has a market cap or net worth of $21.94B. The enterprise value is $22.26B.
Market Cap$21.94B
Enterprise Value$22.26B
Share Statistics
Biogen has 146,614,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding146,614,600
Owned by Insiders0.17%
Owned by Institutions0.26%
Financial Efficiency
Biogen’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 8.79%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)8.79%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee1.27M
Profits Per Employee214.62K
Employee Count7,605
Asset Turnover0.34
Inventory Turnover0.94
Valuation Ratios
The current PE Ratio of Biogen is 14.3. Biogen’s PEG ratio is 0.34.
PE Ratio14.3
PS Ratio2.30
PB Ratio1.33
Price to Fair Value1.33
Price to FCF8.86
Price to Operating Cash Flow9.02
PEG Ratio0.34
Income Statement
In the last 12 months, Biogen had revenue of 9.68B and earned 1.63B in profits. Earnings per share was 11.20.
Revenue9.68B
Gross Profit7.37B
Operating Income2.49B
Pretax Income1.91B
Net Income1.63B
EBITDA3.00B
Earnings Per Share (EPS)11.20
Cash Flow
In the last 12 months, operating cash flow was 2.45B and capital expenditures -176.20M, giving a free cash flow of 2.28B billion.
Operating Cash Flow2.45B
Free Cash Flow2.28B
Free Cash Flow per Share15.53
Dividends & Yields
Biogen pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change-14.02%
50-Day Moving Average144.05
200-Day Moving Average135.16
Relative Strength Index (RSI)56.21
Average Volume (3m)1.64M
Important Dates
Biogen upcoming earnings date is Jan 29, 2026, Before Open (Confirmed).
Last Earnings DateOct 30, 2025
Next Earnings DateJan 29, 2026
Ex-Dividend Date―
Financial Position
Biogen as a current ratio of 1.35, with Debt / Equity ratio of 36.19%
Current Ratio1.35
Quick Ratio0.90
Debt to Market Cap0.28
Net Debt to EBITDA1.42
Interest Coverage Ratio9.95
Taxes
In the past 12 months, Biogen has paid 273.80M in taxes.
Income Tax273.80M
Effective Tax Rate0.14
Enterprise Valuation
Biogen EV to EBITDA ratio is 8.86, with an EV/FCF ratio of 10.55.
EV to Sales2.74
EV to EBITDA8.86
EV to Free Cash Flow10.55
EV to Operating Cash Flow9.23
Balance Sheet
Biogen has $3.96B in cash and marketable securities with $6.59B in debt, giving a net cash position of -$2.63B billion.
Cash & Marketable Securities$3.96B
Total Debt$6.59B
Net Cash-$2.63B
Net Cash Per Share-$17.94
Tangible Book Value Per Share$3.75
Margins
Gross margin is 56.76%, with operating margin of 25.74%, and net profit margin of 16.87%.
Gross Margin56.76%
Operating Margin25.74%
Pretax Margin19.70%
Net Profit Margin16.87%
EBITDA Margin30.96%
EBIT Margin24.00%
Analyst Forecast
The average price target for Biogen is $179.47, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$179.47
Price Target Upside19.96% Upside
Analyst ConsensusModerate Buy
Analyst Count24
Revenue Growth Forecast3.48%
EPS Growth Forecast31.44%